Proteomics

Dataset Information

0

Proteomic response of S. aureus with entrectinib treatment

ABSTRACT: S. aureus isolate was inoculated and cultured to exponential growth phase (OD600 at 0.5) in TSB and divided into two groups, the control group and the drug treated group. Entrectinib was added to the drug treated group until a final concentration of 1/2× MIC reached, and DMSO added in the control group. Then, cultures in both groups were cultivated for 2 h at 200 rpm. The microbial was centrifuged at 12000 rpm for 10 min, washed twice with Phosphate Buffer Saline (PBS). Lyse the cells by bead-beating at 4 °C in RIPA lysis buffer (1% Triton X-100, 1% deoxycholate, 0.1% SDS), The protein reduction, alkylation and tryptic digestion were followed as filter-aided sample preparation (FASP). The digestion products were analyzed with liquid chromatography-electrospray ionization-tandem mass spectrometry (LC-ESI-MS/MS), followed by label-free quantitative analysis. The MS experiment was performed on a Q Exactive plus mass spectrometer.

ORGANISM(S): Staphylococcus Aureus

SUBMITTER: Zhijian Yu  

PROVIDER: PXD038342 | iProX | Wed Nov 23 00:00:00 GMT 2022

REPOSITORIES: iProX

Json Xml
altmetric image

Publications

Inhibition of planktonic growth and biofilm formation of <i>Staphylococcus aureus</i> by entrectinib through disrupting the cell membrane.

Liu Shanghong S   Xiong Yanpeng Y   Xiao Haitao H   Zheng Jinxin J   Wen Zewen Z   Li Duoyun D   Deng Qiwen Q   Yu Zhijian Z  

Frontiers in microbiology 20230109

Over the last few decades, <i>Staphylococcus aureus</i> infection remain a major medical challenge and health concern worldwide. Biofilm formation and antibiotic resistance caused by <i>S. aureus</i> make it difficult to be eradicated from bacterial infections in clinics. In this study, our data demonstrated the antibacterial and excellent anti-biofilm activity of entrectinib against <i>S. aureus</i>. Entrectinib also exhibited the good safety, suggesting no toxicity with antibacterial concentra  ...[more]

Similar Datasets

Proteomics 25μM Loratadine and DMSO control group of Enterococcus faecalis biofilm quantitative proteomics comparative study to observe the global expression of protein DMSO treatment group
2023-06-20 | PXD043125 | iProX
Proteomics Proteomic response of Enterococcus faecalis with Candesartan Cilexetil treatment
2023-08-05 | PXD044400 | iProX
Proteomics Staphylococcus aureus biofilm quantitative proteomics comparative study to observe the global expression of protein DMSO treatment group and radezolid treatment group
2022-11-25 | PXD038354 | iProX
Proteomics The antibacterial mechanism of Loratadine derivative lo-7 against Streptococcus agalactiae
2023-10-20 | PXD046298 | iProX
Proteomics proteomic response of S. aureus with BB-Cl-Amidine treatment
2023-09-05 | PXD045103 | iProX
Proteomics Proteomic response of S. aureus with baohuoside I
2023-07-29 | PXD044207 | iProX
Proteomics Proteomic response of S. aureus with TAK-285 treated
2023-10-24 | PXD046343 | iProX
Proteomics proteomic response of S. aureus with D-3263 treatment
2023-10-24 | PXD046347 | iProX
Proteomics proteomic response of S. aureus with Pinaverium bromide treatment
2023-01-12 | PXD039378 | iProX
Proteomics 1 / 2 MIC Loratadine and DMSO control group of Streptococcus agalactiae quantitative proteomics to observe the global expression of protein in DMSO treatment group and Loratadine group
2023-07-05 | PXD043548 | iProX